Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Pancreatic Cancer
Interventions
DRUG

gemcitabine hydrochloride

1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks

DRUG

Serine Proteinase Inhibitor WX-671

oral, daily

DRUG

Serine Proteinase Inhibitor WX-671

oral, daily

Trial Locations (39)

1097

Szent Laszlo Korhaz, Budapest

18009

Cherkassy Regional Oncology Center, Cherkassy

18014

Hospital Virgen de las Nieves, Granada

28033

Centro Oncologico M.D. Anderson International Espana, Madrid

33081

Centro di Riferimento Oncologico - Aviano, Aviano

36024

Ukrainian Medical Stomatological Academy, Poltava

49600

Dnipropetrovsk State Medical Academy, Dnipropetrovsk

57100

Presidio Ospedaliero di Livorno, Livorno

58002

Bukovinian State Medical University, Chernivtsy

61024

Grigoriev Institute for Radiology Academy of Medical Science of Ukraine, Kharkiv

69120

Otto-Meyerhof-Zentrum Tagesklinik, Heidelberg

76018

Ivano-Frankovsk Regional Oncology Center, Ivano-Frankivsk

80131

Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli, Naples

Istituto Tumori/Fondazione Pascale, Naples

83092

Donetsk Regional Antitumor Center, Donetsk

109033

Moscow Oncology Hospital, Moscow

115478

Russian Academy of Medical Sciences Cancer Research Center, Moscow

121356

Central Clinical Hospital of the President of the Russian Federation, Moscow

197089

Pavlov State Medical University, Saint Petersburg

Saint Petersburg State Medical University, Saint Petersburg

644013

Rostov Research Institute of Oncology - Omsk, Omsk

656049

Altai Oncology Center, Barnaul

D-13353

Charite University Hospital - Campus Virchow Klinikum, Berlin

D-79106

Universitaetsklinikum Freiburg, Freiburg im Breisgau

D-39120

Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg

D-55101

Johannes Gutenberg University, Mainz

D-68305

III Medizinische Klinik Mannheim, Mannheim

D-81377

Klinikum der Universitaet Muenchen - Grosshadern Campus, Munich

D-81675

Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich

D-81925

Hospital Muenchen Bogenhausen, Munich

H-4012

Debreceni Egyetem Onkologiai Tanzek, Debrecen

h-9024

Petz Aladar County Hospital, Gydr

H-7643

University of Pecs Faculty of Medicine, Pécs

H-6720

Szeged University, Szeged

00135

Ospedale San Filippo Neri, Rome

08025

Hospital de la Santa Cruz i Sant Pau, Barcelona

08035

Vall d'Hebron University Hospital, Barcelona

03203

Hospital Universitario de Elche, Elche

03022

Institute of Oncology, Kiev

Sponsors
All Listed Sponsors
lead

Heidelberg Pharma AG

INDUSTRY